American Pharmaceutical Partners Receives FDA Approval for Terbutaline Sulfate Injection
[ Health and Medicine Board ] [ Home ]
Posted by American Pharmaceutical Partners, Inc. on May 28, 2004 at 07:39:44:
SCHAUMBURG, Ill., May 28 /PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc. (Nasdaq: APPX - News) today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Terbutaline Sulfate Injection, USP. Terbutaline is indicated for the prevention and reversal of bronchospasm in patients over the age of 12 with bronchial asthma and reversible bronchospasm associated with bronchitis and emphysema, and is the generic equivalent of aaiPharma Inc.'s Brethine Injection. APP expects to commence marketing terbutaline shortly. 
|